C9057: Injection, cetirizine hydrochloride, 1 mg
C9057 is a HCPCS Level II code for injection, cetirizine hydrochloride, 1 mg. It belongs to the Outpatient Prospective Payment System section. It was terminated on June 30, 2020 and is not valid on new claims.
This code has been terminated
CMS terminated C9057 on June 30, 2020. It stays in the file as history: a claim you are auditing from before that date may legitimately carry it, but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9057
- Long descriptor
- Injection, cetirizine hydrochloride, 1 mg
- Short descriptor
- Inj cetirizine hydrochloride
- Added
- April 1, 2020
- Terminated
- June 30, 2020
- BETOS
- O1E
- Pricing indicator
- 53: Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service: CMS's own analytic grouping.
Statute.
Codes adjacent to C9057
HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If C9057 is not quite right, the correct code is very often within a few positions of it.
- C9049Injection, tagraxofusp-erzs, 10 mcgterminated
- C9050Injection, emapalumab-lzsg, 1 mgterminated
- C9051Injection, omadacycline, 1 mgterminated
- C9052Injection, ravulizumab-cwvz, 10 mgterminated
- C9053Injection, crizanlizumab-tmca, 1 mgterminated
- C9054Injection, lefamulin (xenleta), 1 mgterminated
- C9055Injection, brexanolone, 1mgterminated
- C9056Injection, givosiran, 0.5 mgterminated
- C9058Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo) 0.5 mgterminated
- C9059Injection, meloxicam, 1 mgterminated
- C9060Fluoroestradiol f18, diagnostic, 1 mciterminated
- C9061Injection, teprotumumab-trbw, 10 mgterminated
- C9062Injection, daratumumab 10 mg and hyaluronidase-fihjterminated
- C9063Injection, eptinezumab-jjmr, 1 mgterminated
- C9064Mitomycin pyelocalyceal instillation, 1 mgterminated
- C9065Injection, romidepsin, non-lyophilized (e.g. liquid), 1mgterminated